400-815-1117
2026-01-15
International pharmaceutical leaders and investors gathered in San Francisco on Sunday to explore partnership opportunities with Chinese biotech companies, as the country's out-licensing deals exceeded $130 billion last year and its contribution to the global drug pipeline reached 30 percent.
國際制藥界領袖與投資者周日齊聚舊金山，探索與中國生物科技企業的合作機遇。去年中國醫藥對外授權交易額突破1300億美元，對全球創新藥研發管線貢獻度已達30%。
Organized by the Zhongguancun FIC Innovative Drug Strategic Development Alliance, the 2026 China FIC Innovation and Collaboration Summit served as a global roadshow and launch platform for key Chinese innovative drug projects, facilitating connections between Chinese pharmaceutical companies and international industry leaders while promoting increased multinational investment in China's biotech sector.
由ZFIC聯盟主辦的2026中國FIC創新與合作峰會，為中國重點創新藥項目提供了全球路演與發布平臺，促進了中國藥企與國際產業領袖的對接，并推動跨國資本加大對中國生物科技領域的投資。
"Our journey — from humble 'Me-Too' and 'Me-Better' to transformative 'First-in-Class' — tells a story not just of scientific progress, but of an entirely new ecosystem and a transformed model of global partnership," said the director-general of Beijing Investment Promotion Service Center during the summit."
我們正在從'Me too'和'Me better'到具有變革性的“First in class”轉變，這不僅是一個科學進步的故事，更是一個全新生態系統和全球化合作模式轉型的故事。"北京市投資促進服務中心主任在峰會中表示。
She called the event a "vital two-way bridge" that showcases China's potential to the world while connecting global expertise with Chinese innovation, and said that China's pharmaceutical sector momentum rests on several fundamental pillars.China's massive unified market, with over 1.4 billion people and healthcare coverage for 1.33 billion citizens, provides unparalleled scale for clinical development and commercialization of innovative medicines. The country's regulatory framework has evolved to operate in full compliance with International Council for Harmonisation guidelines, matching leading global standards while balancing innovation incentives with accessibility through volume-based procurement and national reimbursement negotiations, the director-general said.
她稱此次峰會為一座"至關重要的雙向橋梁"，既向世界展示中國潛力，又將全球專業智慧與中國創新相連。她指出，中國醫藥行業的發展動能基于幾大基石：中國擁有超過14億人口的龐大統一市場，其中13.3億公民享有醫療保障，為創新藥的臨床開發和商業化提供了無與倫比的規模優勢；中國的監管體系已全面遵循國際人用藥品注冊技術協調會指南，既對標全球領先標準，又通過帶量采購和國家醫保談判在創新激勵與藥物可及性間取得平衡。
The pace of regulatory approvals has accelerated dramatically, with Chinese authorities approving a record 76 innovative drugs in 2025 alone. These streamlined review timelines have created clearer pathways for synchronized global drug development and launches, she said.
藥品審評審批速度已顯著加快，僅2025年中國就創紀錄地批準了76款創新藥。這些簡化的審評時間線為全球同步研發和上市創造了更清晰的路徑。
China's emergence as a global research and development powerhouse is reflected in its out-licensing deals surpassing $130 billion last year, with approximately 30 percent of the worldwide innovative drug pipeline now being developed in China, according to the director.
中國作為全球研發強國的崛起，體現在去年對外授權交易額突破1300億美元，且全球約30%的創新藥研發管線來自中國。
Despite headwinds facing globalization and rising protectionism, Chinese Consul General in San Francisco Zhang Jianmin said that economic interdependence remains a global reality, with international collaboration essential for finding global solutions.
盡管面臨全球化逆風和保護主義抬頭，中國駐舊金山總領事張建敏表示，經濟相互依存仍是全球現實，國際合作對尋求全球性解決方案至關重要。
"The biopharmaceutical sector is a case in point, because this sector depends so much on global supply chains, cross-border clinical research, data sharing and the spirits of working together among scientists and innovators from around the world," Zhang said."Many of the tasks ahead of us are so complex that they are often beyond the capability of any individual country working alone. China and the United States are the two leading economies and the two leading innovators. If our two countries, our experts and scientists, our industries, are able to work together, it will immeasurably increase the chance of success in getting the most important job done," he said.
"生物制藥領域就是例證，該領域高度依賴全球供應鏈、跨境臨床研究、數據共享以及全球科學家和創新者的協作精神。"他說，"我們面臨的許多任務如此復雜，往往超出任何單一國家獨立應對的能力。中美作為兩大經濟體和創新引領者，若兩國專家、科學家及產業界能攜手合作，將極大提升完成最重要任務的勝算。"
California State Treasurer Fiona Ma echoed this collaborative vision, highlighting the importance of leveraging technology to accelerate research and improve health outcomes. She said that California voters have consistently prioritized healthcare through statewide initiatives, approving bonds for stem cell research, children's hospitals and behavioral health services.
加州財長Fiona Ma呼應了這一合作愿景，強調利用技術加速研究、改善健康成果的重要性。她指出加州選民始終通過全州倡議優先保障醫療健康，批準了用于干細胞研究、兒童醫院和行為健康服務的債券。
"So we have a lot of money now. We are investing in all of these areas. That's why we welcome the partnerships. We should not be doing research and development in our silos now. With the internet, with AI capabilities, we are better able to share our research," Ma said, "and that will expedite discoveries, increase people's health and longevity."
"因此我們現有充足資金正投入這些領域，這也是我們歡迎合作的原因。在互聯網和人工智能時代，我們不應再固守孤島進行研發，而應更好地分享研究成果，這將加速科學發現，增進人民健康與壽命。"
The summit highlighted China's decade-long transformation in pharmaceutical innovation. While the country's innovative drug pipeline has experienced explosive growth and become integral to the global pharmaceutical landscape, with 2025's cross-border licensing value doubling the previous year's scale, only a small percentage of China's new drug pipelines have been involved in transactions, indicating substantial untapped collaboration potential.
峰會凸顯了中國醫藥創新十年的轉型歷程。雖然中國創新藥管線呈爆炸式增長并已成為全球醫藥格局的重要組成部分，2025年跨境授權交易額更達上年規模兩倍，但其中僅小部分新藥管線參與交易，表明仍有巨大的合作潛力尚待開發。
The ZFIC Alliance designed the summit to address this gap by creating an efficient communication platform connecting international pharmaceutical companies, investment institutions and Chinese biotech enterprises. Nine representative projects were selected from nearly 30 roadshow applications for in-person pitching sessions, spanning multiple cutting-edge technology areas and designed to enhance international visibility and collaboration potential.
ZFIC聯盟舉辦此次峰會正是為了填補這一空白，構建連接國際藥企、投資機構與中國生物科技企業的高效溝通平臺。從近30個路演申請中精選的9個代表性項目進行了現場推介，涵蓋多個前沿技術領域，旨在提升國際能見度與合作潛力。
Joseph Scheeren, a member of the French National Academy of Pharmacy with over three decades of pharmaceutical industry experience across the US, Europe and Asia, offered an optimistic assessment of China's trajectory.
擁有逾三十年橫跨美、歐、亞制藥行業經驗的法國國家藥學科學院院士Joseph Scheeren對中國發展路徑給予樂觀評價。
Read in CHINADAILY APP : US-China biotech summit builds bridges for innovative drug partners
